Using the Right Cell for the Right Application: Expanding the Role of Transient Transfection
Pharmaceutical, biopharmaceutical, and biotechnology companies must efficiently identify, develop, and quickly bring to market candidates — whether small molecule drugs, therapeutic proteins, or vaccines — with the highest level of efficacy at the lowest cost.
Read MoreUsing Flow Electroporation to Find More Relevant Candidates and Shorten the Antibody Development Timeline
As the number of biotherapeutics grows, success in the coming years will depend on the ability to get to market quickly. This will involve the ability to work upstream in the manufacturing cell line. While transient gene expression is a rapid and cost-effective means of protein production, particularly during early development and preclinical stages, most transient transfection methods do not meet the requirements of scalability, consistency, speed, and cell type flexibility.
Read MoreScalable, High-Yield Protein Production via Flow Electroporation: Expanding the Use of Transient Gene Expression in Biotherapeutic Development
A variety of factors – including time, resources, quantity requirements, price, as well as scientific drivers such as post translational modifications, protein folding, and regulatory implications – drive the method chosen for protein production during biotherapeutic development.
Read MoreRapid generation of cells for ion channel assays: efficient, large-scale transfection using the MaxCyte® STX™ system, convenient cell culture using Corning® HYPERFlask™ vessels, and robust target activity assayed by the Sophion QPatch
The MaxCyte® STX™ Scalable Transfection System uses a proprietary flow electroporation technology that can transfect up to 1E10 cells with target, reporter and protein expression plasmids, as well as other molecules, in less than 30 minutes.
Read MoreReducing Timelines for Production and Characterization of Bispecifics and Other Novel Scaffolds.
Antibody derivatives, such as bispecifics and Fc fragments, as well as novel scaffolds, represent promising classes of biotherapeutics offering the ability to fine-tune specificity, half-lives, and anti-tumor effector functions.
Read MoreScalable Antibody Production from CHO Cell Line of Choice Using Flow Electroporation
One aspect of lowering costs and reducing attrition rates during biotherapeutic development is the ability to work in the cell line of choice during earlystage discovery. The MaxCyte transfection platform offers a universal means of high efficiency, cell type flexible, and fully scalable protein expression.
Read MoreShortening the Timeline for Drug Development by Enabling Large-Scale TGE in CHO Cells and High Producing Stable CHO Cell Line
To reduce early-stage development costs and lower late-stage attrition rates, many biopharmaceutical companies have turned to transient gene expression (TGE) rather than developing stable cell lines for early-stage development work.
Read MoreSimple and Effective Generation of Cell-based Assays for Ion Channels, Transporters, and Kinase Screening in Biologically Relevant Cells Using Scalable Transient Transfection
Cell-based assays utilizing mammalian cells to express receptor targets are widely used to rapidly identify molecular mechanisms of human disease and to develop novel therapeutics.
Read MoreStrategies for Improved Protein Expression, Production Timelines and Laboratory Productivity Using CHO Cell Transient Expression.
Although protein biotherapeutics continue to have clinical success, companies are challenged to produce new clinical candidates with fewer resources and shortened timelines. Maximizing transient protein production and laboratory productivity play central roles in meeting those challenges, both of which rely on high performance, flexible CHO cell transfection for implementation.
Read MoreTransiently Produced IgGs, Bi-specifics & Fc Fragments with the Quality, Glycosylation & Functionality Required for Use as Surrogates for Stably Produced Proteins in Early-stage Discovery
Companies are turning to transient production of antibodies during early development to delay stable cell line generation, accelerate timelines, and reduce costs.
Read More